Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study.
Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, Bacher U, Staber PB, Mazzeo P, Leng C, Böckle D, Hölscher AS, Kauer J, Rotter N, Vucinic V, Rudzki JD, Nachbaur D, Bücklein VL, Schnetzke U, Krämer I, Wille K, Hasse A, von Tresckow B, Hänel M, Koenecke C, Velazquez GF, Viardot A, Schmid C, Thurner L, Wolf D, Subklewe M, Dreyling M, Dreger P, Dietrich S, Keller U, Jaeger U, Greil R, Pabst T, Lenz G, Chapuy B.
Shumilov E, et al. Among authors: wolf d.
Blood Adv. 2024 Dec 11:bloodadvances.2024014903. doi: 10.1182/bloodadvances.2024014903. Online ahead of print.
Blood Adv. 2024.
PMID: 39661985